Aetion, Cegedim Health Data partner on European RWE effort

By Jenni Spinner contact

- Last updated on GMT

(ClaudioVentrella/iStock via Getty Images Plus)
(ClaudioVentrella/iStock via Getty Images Plus)

Related tags: RWE, RWD, clinical research, Clinical trials, Data management

The two firms will collaborate on an effort to integrate real-world data into clinical trial technology on a broad range of projects.

Aetion and Cegedim Health Data have announced plans to collaborate on technology integrating real-world data (RWD) culled from European sources into trial technology. The collaboration involves integration of Cegedim’s THIN (The Health Improvement Network) European RWD into the Aetion Evidence Platform (AEP).

According to Aetion, the AEP analyzes a range of data—including claims, electronic health records (EHRs), registries, and clinical-trial data—to help produce transparent, rapid, and scientifically-validated real world evidence (RWE) on the safety, effectiveness, and value of medical interventions.

The partnership is intended to empower pharma and biopharma companies, top payers and regulatory agencies to use RDW to uncover new insights about therapies. The THIN data anonymized EHRs from France, UK, Spain, Belgium and Romania, with detail on diagnoses, treatments, clinical outcomes and interventions; it is intended to deliver a robust view of treatment use and outcomes.

Carolyn Magill, CEO of Aetion, said the pharmaceutical development industry must overcome challenges created by the coronavirus pandemic.

Over the last few months, COVID-19 has changed the drug development landscape, as leading biopharma companies, regulators, and health technology assessment bodies (HTAs) alike look to real world data to urgently answer questions on treatment utilization, safety, and effectiveness​,” she said. “Through this partnership with Cegedim, our aim is to help global biopharma companies quickly generate decision-grade real-world evidence by expanding our data sources and capabilities in the EU​.”

Gilles Paubert, global head of Cegedim Health Data, commented that companies can benefit from collaborations such as his, to achieve advancements in development.

The clinically rich data that we capture through THIN, which has a history dating back to 1994, will help clients using Aetion’s platform explore the nuance of each particular dataset, be it therapeutic area-specific or region-specific, to reveal critical insights needed to bring a new drug to market and deliver efficacious treatments to patients faster​,” Paubert said.

Use of RWE is on the rise as stakeholders along the drug development chain strive to accelerate discovery of therapies while overcoming challenges created by the pandemic. The European Medicines Agency (EMA) has announced plans to incorporate RWD to complement evidence from clinical trials and to help streamline regulatory and decision-making processes for COVID-19 vaccine development and authorization.

Related news

Show more

Related products

show more

Overcoming Challenges of Clinical Data Review

Overcoming Challenges of Clinical Data Review

PerkinElmer | 10-Jun-2021 | Technical / White Paper

Clinical data review is intrinsic to clinical development, assuring patient safety, determining drug efficacy, and assessing data quality. It involves...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Related suppliers

Follow us


View more